# IRulya Therapeutics Inc.: Form 8-K, filed Mar 30, 2026

- Company: [IRulya Therapeutics Inc.](/companies/irla.md) (CIK 1662774)
- Form: 8-K
- Filed: 2026-03-30
- Accepted by EDGAR: Mar 30, 2026, 08:35 ET
- Period: 2026-03-27
- Accession: 0001193125-26-130489
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526130489/d57124d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1662774/000119312526130489/

## Items reported

- Item 1.02: Termination of a material agreement
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1662774/000119312526130489/d57124d8k.htm

Filed Mar 30, 2026.
Source: SEC EDGAR, the filing index for accession 0001193125-26-130489. Last ingested by Listed: Nov 5, 2026, 16:02 ET. No prices; not investment advice.